{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T02:34:00Z","timestamp":1781404440958,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.cjca.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T17:57:40Z","timestamp":1337018260000},"page":"334-340","source":"Crossref","is-referenced-by-count":22,"title":["The Evolving Role of \u03b2-Adrenergic Receptor Blockers in Managing Hypertension"],"prefix":"10.1016","volume":"28","author":[{"given":"Luc","family":"Poirier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lacourci\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2012.04.001_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjca.2011.03.015","article-title":"The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy","volume":"27","author":"Rabi","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2012.04.001_bib2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.04.001_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/FJC.0b013e3181ad207b","article-title":"Evolving mechanisms of action of beta blockers: focus on nebivolol","volume":"54","author":"Mason","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.04.001_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results","volume":"304","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2012.04.001_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol","volume":"3","year":"1985","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.04.001_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib8","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.04.001_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.04.001_bib10","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.04.001_bib11","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1517\/14656566.2010.482561","article-title":"Current role of beta-blockers in the treatment of hypertension","volume":"11","author":"Aronow","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cjca.2012.04.001_bib12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should \u00e2-blockers remain first choice in the treatment of primary hypertension?","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2012.04.001_bib13","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2010.04.013","article-title":"One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk","volume":"123","author":"Basile","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2012.04.001_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1254\/jjp.87.7","article-title":"\u03b2-adrenoceptors: three dimensional structures and binding sites for ligands","volume":"87","author":"Nagatomo","year":"2001","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.cjca.2012.04.001_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","article-title":"\u00e2-adrenergic blockers","volume":"13","author":"Frishman","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjca.2012.04.001_bib16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199508103330612","article-title":"The Beta-3 adrenergic receptor--a cause and cure of obesity?","volume":"333","author":"Arner","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.04.001_bib17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","article-title":"Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?","volume":"279","author":"Messerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.04.001_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1751-7176.2009.00140.x","article-title":"Realities of newer beta-blockers for the management of hypertension","volume":"11","author":"Manrique","year":"2009","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib19","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.amjmed.2010.04.014","article-title":"The role of vasodilating beta-blockers in patients with complicated hypertension","volume":"123","author":"Giles","year":"2010","journal-title":"Am J Medicine"},{"key":"10.1016\/j.cjca.2012.04.001_bib20","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.amjcard.2010.08.023","article-title":"Beta-blockers in hypertension","volume":"106","author":"Ram","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.04.001_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/FJC.0b013e31819fd501","article-title":"An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade","volume":"53","author":"Bakris","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.04.001_bib22","series-title":"Cardiovascular Pharmacotherapeutics","first-page":"57","article-title":"Alpha-and beta-adrenergic blocking drugs","author":"Frishman","year":"2011"},{"key":"10.1016\/j.cjca.2012.04.001_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0002-8703(80)90112-X","article-title":"The clinical importance of cardioselectivity and lipophilicity in beta blockers","volume":"100","author":"Cruickshank","year":"1980","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2012.04.001_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002992","article-title":"Cardioselective beta-blockers for reversible airway disease","volume":"4","author":"Salpeter","year":"2002","journal-title":"Cochrane Database of Syst Rev"},{"key":"10.1016\/j.cjca.2012.04.001_bib25","first-page":"940","article-title":"Drug therapy","volume":"308","author":"Frishman","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.04.001_bib26","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/eurheartj\/ehm489","article-title":"Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials","volume":"28","author":"Cucherat","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2012.04.001_bib27","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2010.04.015","article-title":"The role of vasodilating B-blockers in patients with hypertension and the cardiometabolic syndrome","volume":"I23","author":"Taylor","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2012.04.001_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00045391-199406000-00012","article-title":"A double-blind crossover comparison of nebivolol and lisinopril in ambulatory hypertension","volume":"1","author":"Lacourci\u00e8re","year":"1994","journal-title":"Am J Ther"},{"key":"10.1016\/j.cjca.2012.04.001_bib29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/j.1552-4604.1992.tb05778.x","article-title":"Comparative effects of nebivolol and nifedipine on ambulatory blood pressure and plasma lipids, lipoproteins and apolipoproteins","volume":"32","author":"Lacourci\u00e8re","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2012.04.001_bib30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/CIRCULATIONAHA.104.532960","article-title":"Endothelial \u03b23-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol","volume":"112","author":"Dessy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.04.001_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/08038020410016548","article-title":"Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients","volume":"1","author":"Zanchetti","year":"2004","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.cjca.2012.04.001_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.hjh.0000160216.86597.ff","article-title":"Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation","volume":"23","author":"Pasini","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0002-9149(03)00645-3","article-title":"Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension","volume":"92","author":"Kamp","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.04.001_bib34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ajh.2008.156","article-title":"\u00e2-blockers reduced aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection","volume":"21","author":"Mahmud","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib35","first-page":"1955","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials","volume":"355","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.04.001_bib36","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2012.04.001_bib37","series-title":"NICE Clinical Guideline 34","first-page":"8","article-title":"Hypertension: Management of Hypertension in Adults in Primary Care: Pharmacological Update","year":"2006"},{"key":"10.1016\/j.cjca.2012.04.001_bib38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.04.001_bib39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1291\/hypres.31.1135","article-title":"Comparison of arterial functional evaluations as a predictor of cardiovascular events in hypertensive patients: the Non-Invasive Atherosclerotic Evaluation in Hypertension (NOAH) study","volume":"31","author":"Terai","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cjca.2012.04.001_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archfami.7.4.370","article-title":"Fixed low-dose drug combination for the treatment of hypertension","volume":"7","author":"Chrysant","year":"1998","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.cjca.2012.04.001_bib41","first-page":"29","article-title":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.04.001_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ajh\/7.2.137","article-title":"Treatment of ambulatory hypertension with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial-design trial","volume":"7","author":"Lacourci\u00e8re","year":"1994","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-122-2-199501150-00010","article-title":"Effects of antihypertensive therapy on serum lipids","volume":"122","author":"Kasiske","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2012.04.001_bib44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/AC.65.5.2056244","article-title":"Beta-blockers: focus on mechanism of action","volume":"56","author":"Gorr\u00e9","year":"2010","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.cjca.2012.04.001_bib45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00004872-200108000-00011","article-title":"Comparative effects of atenolol and nebivolol on blood pressure and insulin sensitivity in hypertensive patients with glucose intolerance","volume":"19","author":"Poirier","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib46","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/hrt.2006.092379","article-title":"Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)","volume":"93","author":"Torp-Pedersen","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2012.04.001_bib47","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1161\/CIRCULATIONAHA.107.709931","article-title":"Thiazide-type diuretics and B-adrenergic blockers as first-line drug treatments in hypertension","volume":"117","author":"Cutler","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.04.001_bib48","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.04.001_bib49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.04.001_bib50","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.04.001_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1751-7176.2011.00570.x","article-title":"State of the art: evidence-based hypertension treatment in patients with diabetes","volume":"14","author":"Garcia-Touza","year":"2012","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.cjca.2012.04.001_bib52","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1517\/13543784.2011.625011","article-title":"Nebivolol for the treatment of heart failure","volume":"20","author":"Riva","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cjca.2012.04.001_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.04.001_bib54","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.04.001_bib55","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2012.04.001_bib56","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/00005344-198300051-00006","article-title":"Effects of 10 different beta-adrenoreceptor antagonists on hemodynamics, plasma rennin activity and plasma norepinephrine in hypertension: the key role of vascular resistance changes in relation to partial agonist activity","volume":"5","author":"Man in \u2018t Veld","year":"1983","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12001870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12001870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T14:23:21Z","timestamp":1561731801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X12001870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0828282X12001870"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2012.04.001","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}